MIDOL LIQUID GELS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MIDOL LIQUID GELS (MIDOL LIQUID GELS).
Acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis, and elevates pain threshold. Caffeine is a CNS stimulant and adenosine receptor antagonist that enhances analgesic effect. Pyrilamine maleate is an H1-antihistamine with sedative properties. The combination provides analgesic, antipyretic, and antihistaminic effects.
| Metabolism | Acetaminophen: primarily hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1), with minor CYP2E1 oxidation to NAPQI. Caffeine: hepatic CYP1A2. Pyrilamine: hepatic metabolism via hydroxylation and glucuronidation. |
| Excretion | Renal elimination: 85-90% as acetaminophen glucuronide and sulfate conjugates; 5-10% unchanged. Biliary/fecal: minimal (<5%). |
| Half-life | Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose (>12 hours) due to saturable metabolism. Caffeine: 3-5 hours (adults). |
| Protein binding | Acetaminophen: 10-25% (albumin). Caffeine: 35-40% (albumin). |
| Volume of Distribution | Acetaminophen: 0.9-1.1 L/kg (distributes throughout total body water). Caffeine: 0.6-0.8 L/kg. |
| Bioavailability | Oral: 85-95% (acetaminophen); rapidly and completely absorbed from GI tract. |
| Onset of Action | Oral: 10-30 minutes (analgesic effect). |
| Duration of Action | 4-6 hours (analgesic); repeated dosing recommended every 6 hours per labeling. |
2 capsules orally every 6 hours as needed. Maximum 8 capsules in 24 hours.
| Dosage form | CAPSULE |
| Renal impairment | No specific adjustment required for acetaminophen. For caffeine and pyrilamine, no adjustment necessary. For phenylephrine, use with caution if GFR < 30 mL/min due to increased systemic exposure. |
| Liver impairment | Acetaminophen: avoid in severe hepatic impairment (Child-Pugh C). For mild-moderate impairment, maximum 2000 mg/day. Caffeine and pyrilamine: no adjustment. Phenylephrine: no specific recommendation. |
| Pediatric use | Not recommended for children under 12 years. For adolescents ≥12 years, same as adult dosing. |
| Geriatric use | Use with caution due to increased sensitivity to anticholinergic effects (pyrilamine) and cardiovascular effects (phenylephrine). Start with lowest effective dose. Avoid in patients with BPH, glaucoma, or cognitive impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MIDOL LIQUID GELS (MIDOL LIQUID GELS).
| Breastfeeding | Acetaminophen: M/P ratio 0.91-1.42, appears in breast milk but considered safe at therapeutic doses. Caffeine: M/P ratio approximately 0.5-0.8, small amounts excreted; may cause irritability in infants with high maternal intake. Pyrilamine maleate: M/P ratio unknown; minimal excretion expected. Caution in premature infants or those with impaired hepatic function. Monitor infant for drowsiness or irritability. |
| Teratogenic Risk | Midol Liquid Gels contain acetaminophen, caffeine, and pyrilamine maleate. Acetaminophen is generally considered low risk; however, high doses may be associated with fetal hepatic toxicity. Caffeine in moderate amounts is not associated with major malformations, but high intake may increase risk of miscarriage and low birth weight. Pyrilamine maleate has limited data; antihistamines are generally not teratogenic. First trimester: Avoid excessive caffeine. Second and third trimesters: Use lowest effective dose; monitor for fetal effects of caffeine (growth restriction) and antihistamine (neonatal withdrawal if used near term). |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to any component; severe liver disease; concomitant use of other acetaminophen-containing products (relative).
| Precautions | Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g daily. Limit caffeine intake from other sources to avoid toxicity. Caution in patients with liver disease, alcohol use disorder, or hypersensitivity to antihistamines. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate due to caffeine. Assess fetal growth (ultrasound for possible caffeine-related growth restriction). Monitor for signs of acetaminophen hepatotoxicity. In late pregnancy, assess neonatal outcomes (withdrawal symptoms from antihistamine or caffeine). |
| Fertility Effects | Acetaminophen at therapeutic doses is not known to impair fertility. High caffeine intake may delay conception. Pyrilamine maleate has no known direct effects on fertility. Overall, minimal impact on fertility when used per label. |